[1]李倍 任艳琴.胆红素和心血管疾病相关性的研究进展[J].心血管病学进展,2025,(12):1118.[doi:10.16806/j.cnki.issn.1004-3934.2025.12.013]
　LI Bei,REN Yanqin.Bilirubin and Cardiovascular Diseases[J].Advances in Cardiovascular Diseases,2025,(12):1118.[doi:10.16806/j.cnki.issn.1004-3934.2025.12.013]
点击复制

胆红素和心血管疾病相关性的研究进展()

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2025年12期
页码:
1118
栏目:
综述
出版日期:
2025-12-25

文章信息/Info

Title:
Bilirubin and Cardiovascular Diseases
作者:
李倍1 任艳琴 2
(1.山西医科大学汾阳学院,山西 汾阳032200;2.山西医科大学附属汾阳医院心内科,山西 汾阳032200)
Author(s):
LI Bei1; REN Yanqin2
(1. Fenyang College,Shanxi Medical University,Fenyang 032200 ,Shanxi,China;2. Department of Cardiology,Fenyang Hospital Affiliated to Shanxi Medical University,Fenyang 032200,Shanxi,China)
关键词:
胆红素; 心血管疾病; 细胞信号传导; 生物标志物; 治疗
Keywords:
Bilirubin; Cardiovascular disease; Cell signaling; Biomarker; Treatment
DOI:
10.16806/j.cnki.issn.1004-3934.2025.12.013
摘要:
心血管疾病（CVD）是全球首要死因。胆红素作为血红蛋白代谢产物，传统上被认为具有肝毒性；然而近年研究发现，生理及轻度升高浓度的胆红素通过信号通路调控、免疫代谢调节等途径发挥心血管保护作用。血清胆红素水平与动脉粥样硬化、冠心病、心力衰竭和高血压等CVD发生发展密切相关。本文系统阐述了胆红素从传统肝毒性标志物向心血管保护因子认知转变的最新证据，并探讨其在CVD病理生理中的双重角色及治疗潜力，旨在为CVD的预防、诊断和治疗提供新视角。
Abstract:
Cardiovascular disease(CVD) is the leading cause of death worldwide. Bilirubin ,as a metabolic product of hemoglobin,has traditionally been regarded as hepatotoxic. However,recent studies have found that bilirubin at physiological and mildly elevated concentrations exerts cardiovascular protective effects through pathways such as signal transduction regulation and metabolic immune modulation. Higher serum bilirubin levels are associated with a reduced risk and slower progression of CVD ,including atherosclerosis,coronary heart disease,heart failure,and hypertension.The latest data on the switch of bilirubin from an old biomarker of liver toxicity to a protective factor of the cardiovascular system are systematically reviewed in this article. Its dual role in pathophysiology and therapeutic potential for CVD are discussed, in order to provide a new viewpoint on the management of prevention,diagnosis ,and treatment of CVD

参考文献/References:


[1]中国心血管健康与疾病报告2024概要[J]. 中国循环杂志,2025,40(6):521-559.

[2] Vítek L,Tiribelli C. Bilirubin:the yellow hormone?[J]. J Hepatol,2021,75(6):1485-1490.

[3] Seyed Khoei N,Wagner KH,Sedlmeier AM,et al. Bilirubin as an indicator of cardiometabolic health:a cross-sectional analysis in the UK Biobank[J]. Cardiovasc Diabetol,2022,21(1):54.

[4] Vítek L.Bilirubin as a signaling molecule[J]. Med Res Rev,2020,40(4):1335-1351.

[5]Ryter SW. Heme oxygenase-1:an anti-inflammatory effector in cardiovascular,lung,and related metabolic disorders[J]. Antioxidants (Basel),2022,11(3):555.

[6] Nocentini A,Bonardi A,Pratesi S,et al.Pharmaceutical strategies for preventing toxicity and promoting antioxidant and anti-inflammatory actions of bilirubin[J]. J Enzyme Inhib Med Chem,2022,37(1):487-501.

[7] Bock KW. Human AHR functions in vascular tissue:pro- and anti-inflammatory responses of AHR agonists in atherosclerosis[J]. Biochem Pharmacol,2019,159:116-120.

[8] Alonso-Pi?eiro JA,Gonzalez-Rovira A,Sánchez-Gomar I,et al. Nrf2 and heme oxygenase-1 involvement in atherosclerosis related oxidative s tress[J]. Antioxidants (Basel),2021,10(9):1463.

[9] Padda I,Sethi Y,Das M,et al. Heme oxygenase-1,cardiac senescence,and myocardial infarction:a critical r eview of the triptych[J]. Cardiovasc Drugs Ther,2024,Jun 28. DOI:10.1007/s10557-024-07590-0.

[10] Vogel ME,Idelman G,Konaniah ES,et al.Bilirubin prevents atherosclerotic lesion formation in low-density lipoprotein receptor-deficient mice by inhibiting endothelial VCAM-1 and ICAM-1 signaling[J]. J Am Heart Assoc,2017,6(4):e004820.

[11] Longhi MS,Vuerich M,Kalbasi A,et al.Bilirubin suppresses Th17 immunity in colitis by upregulating CD39[J]. JCI Insight,2017,2(9):e92791.

[12]Vitek L,Hinds TD Jr,Stec DE,et al.The physiology of bilirubin:health and disease equilibrium[J]. Trends Mol Med,2023,29(4):315-328.

[13] Ollinger R,Bilban M,Erat A,et al.Bilirubin:a natural inhibitor of vascular smooth muscle cell proliferation[J]. Circulation,2005,112(7):1030-1039.

[14] Lee WH,Kipp ZA,Pauss SN,et al.Heme oxygenase,biliverdin reductase,and bilirubin pathways regulate oxidative stress and insulin resistance:a focus on diabetes and therapeutics[J]. Clin Sci (Lond),2025,139(2):171-198.

[15] Chen W,Tumanov S,Stanley CP,et al. Destabilization of atherosclerotic p laque by bilirubin deficiency[J]. Circ Res,2023,132(7):812-827.

[16] Vítek L,Jirásková A,Malíková I,et al. Serum bilirubin and markers of oxidative stress and inflammation in a healthy population and in patients with various forms of atherosclerosis[J]. Antioxidants (Basel),2022,11(11):2118.

[17]Su Q,Chen H,Du S,et al. Association b etween serum bilirubin,lipid levels,and prevalence of femoral and carotid atherosclerosis:a population-based cross-sectional study[J]. Arterioscler Thromb Vasc Biol,2023,43(1):136-145.

[18] Zhao CC,Wang JW,Chen MY,et al. High-normal serum bilirubin decreased the risk of lower limb atherosclerosis in type 2 diabetes:a real-world study[J]. Diabetol Metab Syndr,2023,15(1):105.

[19] 张雪鹤,刘芬,胡恺轩,等. 血清总胆红素水平与慢血流患者冠心病发病风险的相关性研究[J]. 中国心血管病研究,2023,21(3):240-245.

[20] Yao ME,Su MY,Huang Y,et al. Physiologically increased total bilirubin is associated with reduced risk of first myocardial infarction:a meta-analysis and dose-response analysis[J]. Nutr Metab Cardiovasc Dis,2021,31(4):1016-1026.

[21] Li C,Wu W,Song Y,et al. The nonlinear relationship between total bilirubin and coronary heart disease:a dose-response meta-analysis[J]. Front Cardiovasc Med,2022,8:761520.

[22] Zuo L,Huang J,Zhang H,et al. Dose-response association between bilirubin and cardiovascular disease:a aystematic review and meta-analysis[J]. Angiology,2022,73(10):911-919.

[23] Nilsen DWT,Myhre PL,Solheim S,et al. Total bilirubin yields prognostic information following a myocardial infarction in the elderly[J]. Antioxidants (Basel),2023,12(6):1157.

[24] Li Y,Li DB,Zhao LD,et al. Effects of bilirubin on perioperative myocardial infarction and its long-term prognosis in patients undergoing percutaneous coronary intervention[J]. World J Clin Cases,2022,10(6):1775-1786.

[25] Zhao X,Wang Y,Liu C,et al. Prognostic value of total bilirubin in patients with ST-segment elevation acute myocardial infarction u ndergoing primary coronary intervention[J]. Front Cardiovasc Med,2020,7:615254.

[26] Yang Y,Wang J,Wai Si Ding AJGL,et al. Serum total bilirubin and long-term prognosis of patients with new-onset non-ST elevation myocardial infarction:a cohort study[J]. BMC Cardiovasc Disord,2022,22(1):165.

[27] Lai X,Fang Q,Yang L,et al. Direct,indirect and total bilirubin and risk of incident coronary heart disease in the Dongfeng-Tongji cohort[J]. Ann Med,2018,50(1):16-25.

[28] Xu C,Dong M,Deng Y,et al. Relation of direct,indirect,and total bilirubin to adverse long-term outcomes among patients with acute coronary syndrome[J]. Am J Cardiol,2019,123(8):1244-1248.

[29] 金书媛,李建国. 心肝综合征的研究现状[J]. 中西医结合心脑血管病杂志,2024,22(22):4135-4138.

[30] 何凯,张伦碧. 血清胆红素在慢性心力衰竭的研究进展[J]. 检验医学与临床,2018,15(19):2984-2987.

[31] 蔡志杰,陈培峰,薛君,等. 老年慢性心力衰竭患者胆红素与hs-CRP和NT-proBNP的相关性分析[J]. 中国冶金工业医学杂志,2022,39(1):1-2.

[32] Shiomura R,Kobayashi N,Shirakabe A,et al. Systolic blood pressure and cardiac mortality related to serum total bilirubin levels at admission in patients with acute heart failure[J]. Heart Vessels,2021,36(1):69-75.

[33] Jurkiewicz M,Szczurek-Wasilewicz W,Skrzypek M,et al. Albumin-bilirubin (ALBI) score predicts long-term survival in elderly patients with decompensated heart failure[J]. J Clin Med,2025,14(3):808.

[34] Arthur G,Wasson AR,Straughan RE,et al.The role of renal medullary bilirubin and biliverdin reductase in a ngiotensin Ⅱ-dependent h ypertension[J]. Am J Hypertens,2025,38(4):240-247.

[35] He Z,Zhang S,Thio C,et al.Serum total bilirubin and new-onset hypertension in perimenopausal women:a cross-sectional study[J]. Menopause,2022,29(8):944-951.

[36] 徐美林,陈欣. 老年高血压患者血清总胆红素及肝酶与血压的相关性[J]. 慢性病学杂志,2023,24(10):1458-1461.

[37] Tang C,Jiang H,Zhao B,et al. The association between bilirubin and hypertension among a Chinese ageing cohort:a prospective follow-up study[J]. J Transl Med,2022,20(1):108.

[38] 张玉,高颖,李艳鹏,等. 胆红素血脂综合指数预测原发性高血压发病风险的模型建立与评估[J]. 中国循证心血管医学杂志,2024,16(8):977-982.

[39] Kipp ZA,Badmus OO,Stec DE,et al. Bilirubin bioconversion to urobilin in the gut-liver-kidney axis:a biomarker for insulin resistance in the cardiovascular-kidney-metabolic(CKM) syndrome[J]. Metabolism,2025,163:156081.

[40] Ndumele CE,Rangaswami J,Chow SL,et al. Cardiovascular-kidney-metabolic health:a presidential advisory from the American Heart Association[J]. Circulation,2023,148(20):1606-1635.

[41] 殷钰喆,李喆,吴永健. 心血管-肾脏-代谢综合征视角下动脉粥样硬化性心血管疾病的现状与管理策略[J]. 心血管病学进展,2025,46(4):289-293.

[42] Thomas DT,DelCimmuto NR,Flack KD,et al.Reactive oxygen species(ROS) and antioxidants as immunomodulators in exercise:implications for heme oxygenase and bilirubin[J]. Antioxidants(Basel),2022,11(2):179.

[43] Stec DE,Hinds TD Jr . Natural product heme oxygenase inducers as treatment for nonalcoholic fatty liver disease[J]. Int J Mol Sci,2020,21(24):9493.

[44]Cui Y,Wu C,Li L,et al. Toward nanotechnology-enabled application of bilirubin in the treatment and diagnosis of various civilization diseases[J]. Mater Today Bio,2023,20:100658.

[45]Xiang GQ,Sun FR,Wang BY. [Gilbert’s syndrome:hyperbilirubinemia enemy or friend][J]. Zhonghua Gan Zang Bing Za Zhi,2021,29(10):1024-1027.

[46] Vítek L,Tiribelli C. Gilbert’s syndrome revisited[J]. J Hepatol ,2023,79(4):1049-1055.

相似文献/References:

[1]白春兰,张军.正五聚蛋白-3:新型心血管病炎性标志物[J].心血管病学进展,2016,(1):87.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.023]
　BAI Chunlan,ZHANG Jun.Pentraxin-3: A Novel Inflammation Biomarker for Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2016,(12):87.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.023]
[2]任茂佳,贺文帅,张琪,等.围绝经期对心血管疾病相关危险因素的影响[J].心血管病学进展,2019,(6):911.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.018]
　REN Maojia,HE Wenshuai,ZHANG Qi,et al.Effects of Perimenopause on Cardiovascular Risk Factors[J].Advances in Cardiovascular Diseases,2019,(12):911.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.018]
[3]尹琳 黄从新.JP2蛋白和心血管疾病的研究进展[J].心血管病学进展,2019,(7):1004.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.010]
　YIN Lin HUANG Congxin.Research Progress of JP2 Protein and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(12):1004.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.010]
[4]朱峰 汪汉 蔡琳.抗体与心血管疾病[J].心血管病学进展,2019,(7):1007.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.011]
　ZHU FengWANG HanCAI Lin.Antibodies and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(12):1007.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.011]
[5]邱明仙 王正龙 许官学.心肌肌球蛋白结合蛋白-C磷酸化与心血管疾病关系的研究进展[J].心血管病学进展,2019,(7):1015.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.013]
　QIU MingxianWANG ZhenglongXU Guanxue.Research Progress of the Relationship Between Cardiac Myosin Binding Protein-C and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(12):1015.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.013]
[6]姬楠楠 杨晓静 谢勇.单核细胞/高密度脂蛋白比值与心血管疾病的研究进展[J].心血管病学进展,2019,(7):1019.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.014]
　JI Nannan YANG Xiaojing XIE Yong.Monocyte/High-density Lipoprotein Ratio and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(12):1019.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.014]
[7]渠海贤 李涛 程流泉.人工智能在心脏磁共振成像中的应用进展[J].心血管病学进展,2019,(5):659.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.001]
[8]侯冬华 郝丽荣.长正五聚蛋白3在动脉粥样硬化和心血管疾病中作用研究的新进展[J].心血管病学进展,2019,(5):805.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.035]
　HOU Donghua H AO Lirong.The Study of Atherosclerosis and Cardiovascular Diseases with Pentapycin 3[J].Advances in Cardiovascular Diseases,2019,(12):805.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.035]
[9]张维 张恒 康品方.外泌体在心血管疾病中的研究进展[J].心血管病学进展,2019,(5):818.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.038]
　Zhang WeiKang Pinfang.Exosome in Cardiovascular Diseases[J].Advances in Cardiovascular Diseases,2019,(12):818.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.038]
[10]韦莹 刘书旺 李蕾 崔鸣.生长分化因子-15在心房颤动中的研究进展[J].心血管病学进展,2019,(8):1073.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.001]
　WEI Ying,LIU Shuwang,LI Lei,et al.Growth Differentiation Factor-15 in Development of Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2019,(12):1073.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.001]

更新日期/Last Update: 2026-04-14